Mikhail Kostik

Prof. Dr. Mikhail Kostik

Department of Pediatrics, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
Mikhail KostikMikhail Kostik
Mikhail Kostik
ESEvgeny N. Suspitsin
Evgeny N. Suspitsin
MGMarina N. Guseva
Marina N. Guseva
ALAnastasia S. Levina
Anastasia S. Levina
AKAnastasia Y. Kazantseva
Anastasia Y. Kazantseva
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov

10 November 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
Mikhail KostikMikhail Kostik
Mikhail Kostik
LBLiudmila V. Bregel
Liudmila V. Bregel
IAIlia S. Avrusin
Ilia S. Avrusin
EDElena A. Dondurei
Elena A. Dondurei
AMAlla E. Matyunova
Alla E. Matyunova
VCVyacheslav G. Chasnyk
Vyacheslav G. Chasnyk
Objectives: Diagnostic between multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) and Kawasaki disease (KD) can make difficulties due to many similarities. Our study aimed to create a Kawasaki/MIS-C differentiation score (KMDscore) allowing discrimination of MIS-C and KD.Study design: The retrospective multicenter cohort study included clinical, laboratory, and instrumental information about MIS-C (n = 72) and KD (n = 147). The variables allowed to discriminate both conditions used to construct and validate the diagnostic score called the KMDscore.Results: Patients with MIS-C were older, had earlier admission to the hospital, had a shorter time before fever resolution, two times frequently had signs of GI and CNS involvement observed, and had more impressive thrombocytopenia, higher level of CRP, ferritin, ALT, AST, LDH, creatinine, triglycerides, troponin, and D-dimer compared to KD patients. Respiratory signs in MIS-C were presented with pleuritis, acute respiratory distress syndrome, oxygen dependency, lung infiltration, and ground-glass opacities in CT. The heart involvement with fast progression of myocarditis provided the severity of MIS-C and ICU admission due to 12 times higher arterial hypotension or shock and required cardiotonic. No differences in the frequency of CA lesions were seen in the majority of cases. Five criteria, CRP >11 mg/dl (18 points), D-dimer >607 ng/ml (27 points), age >5 years (30 points), thrombocytopenia (25 points), and GI involvement (28 points), were included in the KMDscore. The summa >55 points allowed to discriminate MIS-C from KD with a sensitivity of 87.5% and specificity of 89.1%.Conclusion: The KMDscore can be used to differentiate the diagnostic of MIS-C from KD.

8 February 2022 in Frontiers in Pediatrics
Verified
Journal Article
Open access
Mikhail KostikMikhail Kostik
Mikhail Kostik
RRRinat K. Raupov
Rinat K. Raupov
ESEvgeny N. Suspitsin
Evgeny N. Suspitsin
EIEugenia A. Isupova
Eugenia A. Isupova
EGEkaterina V. Gaidar
Ekaterina V. Gaidar
VCVyacheslav G. Chasnyk
Vyacheslav G. Chasnyk
JAK-inhibitors are small molecules blocking the JAK-STAT pathway that have proven effective in the treatment of different immune-mediated diseases in adults and juvenile idiopathic arthritis (JIA).Aim of Study: To evaluate the safety and efficacy of tofacitinib in children with different rheumatic diseases.Material and Methods: We extracted information from 24 children with the following diagnosis: JIA (n = 15), undifferentiated systemic autoinflammatory diseases (SAIDs) (n = 7), and juvenile dermatomyositis (JDM) (n = 2) who have been treated with tofacitinib for a period of longer than 6 months. The treatment outcomes were classified according to the opinion of the attending physicians as having a complete response (CR), i.e., the absence of disease activity, or a partial response (PR)—a significant improvement of symptoms and disease activity, or no response (NR)—no changes in disease activity.Results: CR was achieved in 10/24 patients; 7/15 among JIA patients, 1/2 among JDM patients, 4/7 among SAID patients, and PR in 5/15 of JIA, 1/2 of JDM, and 3/7 of SAID patients. Three non-responders with JIA discontinued tofacitinib. Corticosteroids were successfully tapered off in 11/14 patients and discontinued in 2/14 patients. Four patients had side effects not requiring treatment discontinuation: liver enzyme elevation (n = 2), hypercholesterolemia (n = 1), lymphadenitis (n = 1).Conclusion: JAK-inhibitors are effective new therapies for the treatment of multiple immune-mediated diseases. Our experience has shown the best results in patients with JIA and JIA-associated alopecia, and type I interferonopathies. More data from randomized controlled clinical trials are needed to use JAK-inhibitors safely in pediatric rheumatic diseases.

1 February 2015 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
Mikhail KostikMikhail Kostik
Mikhail Kostik
MDMargarita F. Dubko
Margarita F. Dubko
VMVera V. Masalova
Vera V. Masalova
LSLudmila S. Snegireva
Ludmila S. Snegireva
TKTatyana L. Kornishina
Tatyana L. Kornishina
VCVyacheslav Chasnyk
Vyacheslav Chasnyk
The purpose of our study was to detect early clinical and laboratory signs that help to discriminate macrophage activation syndrome (MAS) from active systemic juvenile idiopathic arthritis (SJIA) without MAS.Our retrospective study was based on reviewing the medical charts of the children admitted to the rheumatology department with active SJIA and definite MAS (n = 18) and without MAS (n = 40). We evaluated the data related to SJIA and MAS at the moment of the patient׳s admission. If the patient had signs of MAS since admission or developed definite MAS later during this flare, he was referred to the main group. The children who did not have MAS during the flare episode and did not have MAS in the past medical history were in the control group. We calculated the cutoff points for MAS parameters, performed the analysis of sensitivity and specificity, identified the predictors, and provided the preliminary diagnostic rule through "the-number-of-criteria-present" approach.The clinical signs were relevant to MAS in SJIA: oligoarticular disease course (OR = 5.6), splenomegaly (OR = 67.6), hemorrhages (OR = 33.0), and respiratory failure (OR = 11.3). The involvement of wrist (OR = 0.2), MCP (OR = 0.1), and PIP joints (OR = 0.1) was protective against MAS development. The best cutoffs for laboratory parameters were PLT ≤ 211 × 10(9)/l, WBC ≤ 9.9 × 10(9)/l, AST > 59.7U/l, LDH > 882U/l, albumin ≤ 2.9g/dl, ferritin > 400μg/l, fibrinogen ≤ 1.8g/l, and proteinuria. The laboratory variables were more precise in the discrimination of early MAS than clinical: any 3 or more laboratory criteria provided the highest specificity (1.0) and sensitivity (1.0) and OR = 2997.We detected clinical and laboratory markers and created preliminary diagnostic (laboratory) guidelines for early discrimination of MAS in active SJIA.


31 August 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
Mikhail KostikMikhail Kostik
Mikhail Kostik
OKOlga L. Kopchak
Olga L. Kopchak
ICIrina Alexandrovna Chikova
Irina Alexandrovna Chikova
EIEugenia A. Isupova
Eugenia A. Isupova
AMAlexander Mushkin
Alexander Mushkin